This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Malet, I.
Right arrow Articles by Marcelin, A.-G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Malet, I.
Right arrow Articles by Marcelin, A.-G.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2008, p. 1351-1358, Vol. 52, No. 4
0066-4804/08/$08.00+0     doi:10.1128/AAC.01228-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In Vitro{triangledown}

Isabelle Malet,1* Olivier Delelis,2 Marc-Antoine Valantin,3,4 Brigitte Montes,5 Cathia Soulie,1 Marc Wirden,1 Luba Tchertanov,2 Gilles Peytavin,6 Jacques Reynes,5 Jean-François Mouscadet,2 Christine Katlama,3,4 Vincent Calvez,1 and Anne-Geneviève Marcelin1

Laboratoire de Virologie, Hôpital Pitié-Salpêtrière, Assistance Publique—Hôpitaux de Paris, EA 2387, Université Pierre et Marie Curie (Paris 6), Paris,1 LBPA, CNRS, Ecole Normale Supérieure de Cachan, Cachan,2 INSERM U720, Université Pierre et Marie Curie (Paris 6), Paris,3 Service des Maladies Infectieuses, Hôpital Pitié-Salpêtrière, Paris,4 Pôle Infectiologie, CHU de Montpellier, 34 295 Montpellier,5 Service de Pharmacie Clinique, Hôpital Bichat-Claude-Bernard, 46, rue Henri-Huchard, 75018 Paris, France6

Received 18 September 2007/ Returned for modification 9 November 2007/ Accepted 16 January 2008

Raltegravir (MK-0518) is a potent inhibitor of human immunodeficiency virus (HIV) integrase and is clinically effective against viruses resistant to other classes of antiretroviral agents. However, it can select mutations in the HIV integrase gene. Nine heavily pretreated patients who received salvage therapy including raltegravir and who subsequently developed virological failure under raltegravir therapy were studied. For each patient, the sequences of the integrase-coding region were determined and compared to that at the beginning of the treatment. Four different mutation profiles were identified in these nine patients: E92Q, G140S Q148H, N155H, and E157Q mutations. For four patients, each harboring a different profile, the wild-type and mutated integrases were produced, purified, and assayed in vitro. All the mutations identified altered the activities of integrase protein: both 3' processing and strand transfer activities were moderately affected in the E92Q mutant; strand transfer was markedly impaired in the N155H mutant; both activities were strongly impaired in the G140S Q148H mutant; and the E157Q mutant was almost completely inactive. The sensitivities of wild-type and mutant integrases to raltegravir were compared. The E92Q and G140S Q148H profiles were each associated with a 7- to 8-fold decrease in sensitivity, and the N155H mutant was more than 14-fold less sensitive to raltegravir. At least four genetic profiles (E92Q, G140S Q148H, N155H, and E157Q) can be associated with in vivo treatment failure and resistance to raltegravir. These mutations led to strong impairment of enzymes in vitro in the absence of raltegravir: strand transfer activity was affected, and in some cases 3' processing was also impaired.

* Corresponding author. Mailing address: Hôpital Pitié-Salpêtrière, Laboratoire de Virologie (bâtiment CERVI), 83 boulevard de l'hôpital, 75013 Paris, France. Phone: 33-1-42 17 74 01. Fax: 33-1-42 17 74 11. E-mail: isabelle.malet{at}psl.aphp.fr

{triangledown} Published ahead of print on 28 January 2008.

Antimicrobial Agents and Chemotherapy, April 2008, p. 1351-1358, Vol. 52, No. 4
0066-4804/08/$08.00+0     doi:10.1128/AAC.01228-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Fransen, S., Gupta, S., Danovich, R., Hazuda, D., Miller, M., Witmer, M., Petropoulos, C. J., Huang, W. (2009). Loss of Raltegravir Susceptibility by Human Immunodeficiency Virus Type 1 Is Conferred via Multiple Nonoverlapping Genetic Pathways. J. Virol. 83: 11440-11446 [Abstract] [Full Text]  
  • Wirden, M., Simon, A., Schneider, L., Tubiana, R., Malet, I., Ait-Mohand, H., Peytavin, G., Katlama, C., Calvez, V., Marcelin, A.-G. (2009). Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drug. J Antimicrob Chemother 64: 1087-1090 [Abstract] [Full Text]  
  • Low, A., Prada, N., Topper, M., Vaida, F., Castor, D., Mohri, H., Hazuda, D., Muesing, M., Markowitz, M. (2009). Natural Polymorphisms of Human Immunodeficiency Virus Type 1 Integrase and Inherent Susceptibilities to a Panel of Integrase Inhibitors. Antimicrob. Agents Chemother. 53: 4275-4282 [Abstract] [Full Text]  
  • Ntemgwa, M. L., Toni, T. d., Brenner, B. G., Camacho, R. J., Wainberg, M. A. (2009). Antiretroviral Drug Resistance in Human Immunodeficiency Virus Type 2. Antimicrob. Agents Chemother. 53: 3611-3619 [Full Text]  
  • Choudhary, S. K., Rezk, N. L., Ince, W. L., Cheema, M., Zhang, L., Su, L., Swanstrom, R., Kashuba, A. D. M., Margolis, D. M. (2009). Suppression of Human Immunodeficiency Virus Type 1 (HIV-1) Viremia with Reverse Transcriptase and Integrase Inhibitors, CD4+ T-Cell Recovery, and Viral Rebound upon Interruption of Therapy in a New Model for HIV Treatment in the Humanized Rag2-/-{gamma}c-/- Mouse. J. Virol. 83: 8254-8258 [Abstract] [Full Text]  
  • Ghosn, J., Mazet, A.-A., Avettand-Fenoel, V., Peytavin, G., Wirden, M., Delfraissy, J.-F., Chaix, M.-L. (2009). Rapid selection and archiving of mutation E157Q in HIV-1 DNA during short-term low-level replication on a raltegravir-containing regimen. J Antimicrob Chemother 64: 433-434 [Full Text]  
  • Sichtig, N., Sierra, S., Kaiser, R., Daumer, M., Reuter, S., Schulter, E., Altmann, A., Fatkenheuer, G., Dittmer, U., Pfister, H., Esser, S. (2009). Evolution of raltegravir resistance during therapy. J Antimicrob Chemother 64: 25-32 [Abstract] [Full Text]  
  • Malet, I., Delelis, O., Soulie, C., Wirden, M., Tchertanov, L., Mottaz, P., Peytavin, G., Katlama, C., Mouscadet, J.-F., Calvez, V., Marcelin, A.-G. (2009). Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients. J Antimicrob Chemother 63: 795-804 [Abstract] [Full Text]  
  • Delelis, O., Malet, I., Na, L., Tchertanov, L., Calvez, V., Marcelin, A.-G., Subra, F., Deprez, E., Mouscadet, J.-F. (2009). The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation. Nucleic Acids Res 37: 1193-1201 [Abstract] [Full Text]  
  • Paar, C., Palmetshofer, C., Flieger, K., Geit, M., Kaiser, R., Stekel, H., Berg, J. (2008). Genotypic Antiretroviral Resistance Testing for Human Immunodeficiency Virus Type 1 Integrase Inhibitors by Use of the TruGene Sequencing System. J. Clin. Microbiol. 46: 4087-4090 [Abstract] [Full Text]  
  • McKee, C. J., Kessl, J. J., Shkriabai, N., Dar, M. J., Engelman, A., Kvaratskhelia, M. (2008). Dynamic Modulation of HIV-1 Integrase Structure and Function by Cellular Lens Epithelium-derived Growth Factor (LEDGF) Protein. J. Biol. Chem. 283: 31802-31812 [Abstract] [Full Text]  
  • Goethals, O., Clayton, R., Van Ginderen, M., Vereycken, I., Wagemans, E., Geluykens, P., Dockx, K., Strijbos, R., Smits, V., Vos, A., Meersseman, G., Jochmans, D., Vermeire, K., Schols, D., Hallenberger, S., Hertogs, K. (2008). Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase Inhibitors. J. Virol. 82: 10366-10374 [Abstract] [Full Text]  
  • Havlir, D. V. (2008). HIV Integrase Inhibitors -- Out of the Pipeline and into the Clinic. NEJM 359: 416-418 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»